[HTML][HTML] Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–rich …
Journal of clinical oncology, 2011•ncbi.nlm.nih.gov
Purpose Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving
surgery (BCS) for estrogen receptor (ER)–positive breast cancer. To study this treatment
option, responses to three AIs were compared in a randomized phase II neoadjuvant trial
designed to select agents for phase III investigations.
surgery (BCS) for estrogen receptor (ER)–positive breast cancer. To study this treatment
option, responses to three AIs were compared in a randomized phase II neoadjuvant trial
designed to select agents for phase III investigations.
Abstract
Purpose
Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)–positive breast cancer. To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations.
ncbi.nlm.nih.gov